Edition:
United Kingdom

Amgen Inc (AMGN.OQ)

AMGN.OQ on NASDAQ Stock Exchange Global Select Market

186.70USD
22 Mar 2019
Change (% chg)

$-5.19 (-2.70%)
Prev Close
$191.89
Open
$190.96
Day's High
$192.83
Day's Low
$186.55
Volume
1,470,150
Avg. Vol
1,334,971
52-wk High
$210.18
52-wk Low
$163.31

Latest Key Developments (Source: Significant Developments)

Regeneron And Sanofi Disagree With Verdict Upholding 3 Of 5 Amgen U.S. Patent Claims Relating To PCSK9 Antibodies
Monday, 25 Feb 2019 

Feb 25 (Reuters) - Regeneron Pharmaceuticals Inc ::REGENERON AND SANOFI STRONGLY DISAGREE WITH VERDICT UPHOLDING THREE OF FIVE AMGEN U.S. PATENT CLAIMS RELATING TO PCSK9 ANTIBODIES.REGENERON PHARMACEUTICALS INC - CONTINUE TO BELIEVE IN DIFFERENTIATED CLINICAL PROFILE OF PRALUENT.REGENERON - CO, SANOFI TO FILE POST-TRIAL MOTIONS WITH DISTRICT COURT OVER NEXT FEW MONTHS, SEEKING TO OVERTURN JURY VERDICT & REQUESTING NEW TRIAL.REGENERON PHARMACEUTICALS INC - IF NECESSARY SANOFI, CO PLAN TO APPEAL TO U.S. COURT OF APPEALS FOR FEDERAL CIRCUIT.REGENERON PHARMACEUTICALS INC - VERDICT DOES NOT IMPACT U.S. PHYSICIANS' AND PATIENTS' ACCESS TO PRALUENT.  Full Article

Jury Upholds Amgen's Patents On Repatha (Evolocumab)
Monday, 25 Feb 2019 

Feb 25 (Reuters) - Amgen Inc ::JURY UPHOLDS AMGEN'S PATENTS ON REPATHA® (EVOLOCUMAB).AMGEN INC - JURY DELIVERED A VERDICT IN AMGEN'S FAVOR UPHOLDING VALIDITY OF TWO AMGEN PATENTS RELATED TO PCSK9 ANTIBODIES.AMGEN INC - JURY FOUND THAT AMGEN PATENTS MEET LEGAL REQUIREMENTS OF WRITTEN DESCRIPTION AND ENABLEMENT.AMGEN INC - AMGEN IS SEEKING TO ENFORCE PCSK9 ANTIBODY PATENTS PATENTS IN NATIONAL COURTS IN EUROPE AND JAPAN AGAINST SANOFI AND REGENERON.  Full Article

Abilita Bio And Amgen Enter Into A Multi-Target Collaboration
Wednesday, 13 Feb 2019 

Feb 13 (Reuters) - ABILITA BIO ::ABILITA BIO AND AMGEN ENTER INTO A MULTI-TARGET COLLABORATION.ABILITA BIO - FINANCIAL DETAILS WERE NOT DISCLOSED.ABILITA BIO - CO TO LEVERAGE MEMBRANE PROTEIN TECHNOLOGY PLATFORM TO SUPPORT AMGEN'S RESEARCH AND DEVELOPMENT EFFORTS ON INTEGRAL MEMBRANE PROTEIN TARGETS.  Full Article

Amgen Reports 5.9 Percent Passive Share Stake In Kezar Life Sciences Inc As Of Dec 31
Friday, 8 Feb 2019 

Feb 8 (Reuters) - Amgen Inc ::AMGEN INC REPORTS 5.9 PERCENT PASSIVE SHARE STAKE IN KEZAR LIFE SCIENCES INC AS OF DEC 31, 2018 .  Full Article

Amgen Expects Mid-Single-Digit Global Net Price Decline In 2019
Tuesday, 29 Jan 2019 

Jan 29 (Reuters) - Amgen Inc ::AMGEN INC CFO DAVID MELINE SAYS COMPANY EXPECTS MID-SINGLE-DIGIT GLOBAL NET PRICE DECLINE IN 2019.  Full Article

Amgen Inc Q4 GAAP Earnings Per Share $3.01
Tuesday, 29 Jan 2019 

Jan 29 (Reuters) - Amgen Inc ::AMGEN INC Q4 GAAP EARNINGS PER SHARE $3.01, Q4 ADJUSTED EARNINGS PER SHARE $3.42.AMGEN INC Q4 TOTAL REVENUE $6.23 BILLION, UP 7 PERCENT.AMGEN INC Q4 EARNINGS PER SHARE VIEW $3.27, REVENUE VIEW $5.84 BILLION -- REFINITIV IBES DATA.AMGEN INC SEES 2019 EARNINGS PER SHARE $11.55 TO $12.75, SEES 2019 ADJUSTED EARNINGS PER SHARE $13.10 TO $14.30.AMGEN INC SEES 2019 TOTAL REVENUE $21.8 BILLION TO $22.9 BILLION.AMGEN INC FY 2019 EARNINGS PER SHARE VIEW $14.61, REVENUE VIEW $22.91 BILLION -- REFINITIV IBES DATA.AMGEN INC SEES 2019 CAPITAL EXPENDITURES ABOUT $700 MILLION.  Full Article

Coherus Biosciences Files Patent Infringement Suit Against Amgen
Friday, 25 Jan 2019 

Jan 25 (Reuters) - Coherus BioSciences Inc ::COHERUS BIOSCIENCES ANNOUNCES FILING OF PATENT INFRINGEMENT SUIT AGAINST AMGEN DIRECTED TO AMGEN’S HUMIRA BIOSIMILAR FORMULATION.COHERUS BIOSCIENCES - EACH OF ASSERTED COHERUS PATENTS IS DIRECTED TO STABLE FORMULATIONS OF ADALIMUMAB.COHERUS BIOSCIENCES - CONTINUES TO EVALUATE OPTIONS AND POTENTIAL STRATEGIES FOR EX-U.S. COMMERCIALIZATION OF CHS-1420.  Full Article

Amgen And Allergan Announce Positive Top-Line Results From Phase 1/ Phase 3 Study Of Abp 798, Biosimilar Candidate To Rituximab
Thursday, 24 Jan 2019 

Jan 24 (Reuters) - Allergan plc ::AMGEN AND ALLERGAN ANNOUNCE POSITIVE TOP-LINE RESULTS FROM PHASE 1/ PHASE 3 STUDY OF ABP 798, BIOSIMILAR CANDIDATE TO RITUXIMAB.AMGEN INC - STUDY EVALUATED PHARMACOKINETICS, EFFICACY AND SAFETY OF ABP 798 COMPARED TO RITUXIMAB IN PATIENTS WITH MODERATE-TO-SEVERE RHEUMATOID ARTHRITIS.AMGEN INC - RESULTS DEMONSTRATE THAT STUDY MET ITS PRIMARY ENDPOINT OF PHARMACOKINETIC (PK) SIMILARITY.AMGEN INC - ADDITIONALLY, EQUIVALENT EFFICACY WAS ESTABLISHED AND A SIMILAR SAFETY PROFILE WAS DEMONSTRATED.  Full Article

BRIEF-Teva And Amgen Resolve Ongoing Dispute Over Teva's Generic Cinacalcet HCl Product
Thursday, 3 Jan 2019 

Corrects spelling of drug in headline and first bullet:TEVA AND AMGEN RESOLVE ONGOING DISPUTE OVER TEVA'S GENERIC CINACALCET HCL PRODUCT.TEVA WILL PAY AMGEN AN UNDISCLOSED AMOUNT AS PART OF THE SETTLEMENT.THE AMOUNT AND OTHER TERMS OF SETTLEMENT REMAIN CONFIDENTIAL.TEVA PHARMACEUTICAL INDUSTRIES- LITIGATION BETWEEN PARTIES TO BE ENDED.TEVA PHARMACEUTICAL INDUSTRIES- CO AGREED TO STOP SELLING ITS GENERIC PRODUCT UNTIL LICENSE DATE IN MID 2021, OR EARLIER UNDER CERTAIN CIRCUMSTANCES.  Full Article

Amgen And Molecular Partners Announce Strategic Collaboration In Immuno-Oncology
Wednesday, 19 Dec 2018 

Dec 18 (Reuters) - :AMGEN AND MOLECULAR PARTNERS ANNOUNCE STRATEGIC COLLABORATION IN IMMUNO-ONCOLOGY.AMGEN-AMGEN AND MOLECULAR PARTNERS ANNOUNCE STRATEGIC COLLABORATION IN IMMUNO-ONCOLOGY.AMGEN-MOLECULAR PARTNERS WILL RECEIVE UPFRONT PAYMENT OF $50 MILLION.AMGEN-PARTIES WILL SHARE CLINICAL DEVELOPMENT COSTS IN DEFINED PERCENTAGES FOR FIRST THREE INDICATIONS SUBJECT TO CERTAIN CONDITIONS.AMGEN-FOR ALL ADDITIONAL CLINICAL TRIALS, AMGEN IS RESPONSIBLE FOR ALL DEVELOPMENT COSTS.AMGEN - MOLECULAR PARTNERS ELIGIBLE TO RECEIVE UP TO $497 MILLION IN DEVELOPMENT, REGULATORY AND COMMERCIAL MILESTONE PAYMENTS.AMGEN - PARTIES WILL JOINTLY EVALUATE MP0310 IN COMBINATION WITH AMGEN'S ONCOLOGY PIPELINE PRODUCTS.AMGEN-ANTICIPATE MP0310 TO ENTER CLINIC IN 2019.  Full Article

Amarin's Vascepa cuts occurrence of serious heart problems 30 pct -study

March 18 A high dose of Amarin Corp's Omega-3 drug Vascepa significantly reduced the occurrence of first and subsequent heart attacks, strokes and other serious heart problems in high-risk patients already taking cholesterol medication by even more than initially reported, according to data presented on Monday.